Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
1. Efficacy and Safety of Approved Chimeric Antigen Receptor (CAR) T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) – Systematic Review and Meta-Analysis of Clinical Trials 2022 ISPOR Europe, Abstract No: CO128
2. Cost-effectiveness analysis of Pembrolizumab versus Nivolumab as the First-line treatment for Advanced and Metastatic Non-Small Cell Lung Cancer in Germany
2021, ISPOR Europe, Abstract No: PCN36 ( DOI:https://doi.org/10.1016/j.vhri.2020.07.086 )
3. Cost-effectiveness analysis of Pembrolizumab versus Nivolumab as the First-line treatment for Advanced and Metastatic Non-Small Cell Lung Cancer in France
2021, ISPOR Europe, Abstract No: PCN37 ( DOI:https://doi.org/10.1016/j.vhri.2020.07.087 )
4. Cost-effectiveness analysis of Pembrolizumab versus Nivolumab as the First-line treatment for Advanced and Metastatic Non-Small Cell Lung Cancer (NSCLC) in UK
2021, ISPOR Europe, Abstract No: PCN40 ( DOI:https://doi.org/10.1016/j.jval.2020.04.1599 )
5. Efficacy and Safety of PD-1/PD-L1 Inhibitors used in the treatment of Advanced and Metastatic Melanoma - A Systematic Review and Meta-analysis
2020, ISPOR US Orlando, Abstract No: PCN154
6. Efficacy and Safety of PD-1/PD-L1 Inhibitors used in the management of previously treated Advanced and Metastatic Non-Small Cell Lung Cancer (NSCLC) - Systematic Review and Network Meta-analysis of RCTs
2018, ISPOR US Baltimore, Abstract No: PCN12
7. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens
Medicine, Volume 94, Number 42, October 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620781/pdf/medi-94-e1677.pdf)
8. Association of 5HIAA and Mortality in Neuroendocrine Tumor Patients: A Systematic Review and Meta-Analysis
NANETS 2018 Symposium Abstracts Abstract No: P-8 (https://nanets.net/abstracts-archive/2018/944-abstract-p8/file)
9. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0127960 June 3, 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454514/?report=reader)
10. Cos-Utility of Trabectedin 0.25mg and 1mg powder for concentrate for solution for infusion (Yondelis®) used in the treatment of Soft Tissue Sarcoma (STS)
SMC 2021 submission (https://www.scottishmedicines.org.uk/medicines-advice/trabectedin-yondelis-resub-smc2283)
11. Efficacy and Safety of Pacemakers in the management of patients with Bradycardia - A Systematic Review of RCTs
2019 ISPOR Europe, Abstract No: PMD1 ( DOI:https://doi.org/10.1016/j.jval.2019.09.1414 )
12. Singh S, Sharma A, Monga V, Bhatia R. Compendium of naringenin: Potential sources, analytical aspects, chemistry, nutraceutical potentials and pharmacological profile. Critical Reviews in Food Science and Nutrition, 2022, 1-32, Impact Factor 11.20, ISSN: 1549-7852 (web)https://doi.org/10.1080/10408398.2022.2056726
13. Singh, S; Monga, V; Bhatia, R. Impact of Fluorescence based Analytical Techniques in Cancer Management: An Update. Current Analytical Chemistry, 2022, 18, 1-5, IF: 2.37, ISSN: 1875-6727, https://doi.org/10.2174/1573411018666220519105216
14. Kumari K, Singh G, Pradhan T, Bhurta D, Monga V. The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review. Archive der Pharmazie, 2022; e2100517, 1-36, Impact Factor 4.61, ISSN: 1875-6190, https://doi.org/10.1002/ardp.202100517
15. Singh, K.; Bhatia, R.; Kumar, B.; Singh, G, Monga, V. Design strategies, Chemistry, and therapeutic insights of multi-target directed ligands as antidepressant agents. Current Neuropharmacology, 20(7), 2022, 1329-1358. Impact Factor 7.70, ISSN: 0223-5234. DOI:10.2174/1570159X19666211102154311
16. Pradhan, T.; Gupta, G.; Singh, G, Monga, V. Aurora kinase inhibitors as potential anticancer agents: Recent advances. European Journal of Medicinal Chemistry, 221, 2021, 113495. Impact Factor 6.5, ISSN: 0223-5234. https://doi.org/10.1016/j.ejmech.2021.113495
17. Yadav, AK, Kumar, S, Monga V. Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic. Acta Scientific Pharmaceutical Sciences, 5(6), 2021, 45-62, IF = 1.02, ISSN: 2581-5423.
18. Gaba, S.; Saini, A.; Singh, G, Monga, V. An insight into the medicinal attributes of berberine derivatives: A review. Bioorganic & Medicinal Chemistry, 38, 2021, 116143. Impact Factor 3.64, ISSN: 0968-0896. https://doi.org/10.1016/j.bmc.2021.116143
19. Rulhania, S.; Kumar, S.; Nehra, B.; Gupta, GD, Monga, V. An insight into the medicinal perspective of synthetic analogs of imidazole. Journal of Molecular Structure, 1232, 2021, 129982. Impact Factor: 3.19, ISSN: 0022-2860. https://doi.org/10.1016/j.molstruc.2021.129982
20. Shubham Kumar, Sandeep Rulhania, Shalini Jaswal, Monga, V. Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. European Journal of Medicinal Chemistry, 2021, 209, 112923. Impact Factor: 6.5, ISSN: 0223-5234. https://doi.org/10.1016/j.ejmech.2020.112923
We believe that the key to success is a collaborative approach that puts your needs first. Our team works closely with you every step of the way to ensure that our solutions are aligned with your goals and objectives.